UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 31

Sortiert nach

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

Leukemia, 2014-01, Vol.28 (1), p.78-87

2014

Link zum Volltext

Verfügbarkeit prüfen

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors

Leukemia, 2012-02, Vol.26 (2), p.244-254

2012

Link zum Volltext

Verfügbarkeit prüfen

Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron

Leukemia, 2015-01, Vol.29 (1), p.188-195

2015

Link zum Volltext

Verfügbarkeit prüfen

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

Leukemia, 2010-10, Vol.24 (10), p.1799-1804

2010

Link zum Volltext

Verfügbarkeit prüfen

A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome

Blood, 2003-10, Vol.102 (8), p.3025-3027

2003

Link zum Volltext

Verfügbarkeit prüfen

p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia

Leukemia, 2011-11, Vol.25 (11), p.1739-1750

2011

Link zum Volltext

Verfügbarkeit prüfen

CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors

Leukemia, 2012-07, Vol.26 (7), p.1547-1554

2012

Link zum Volltext

Verfügbarkeit prüfen

Fludarabine i.v. BU conditioning regimen: myeloablative, reduced intensity or both?

Bone marrow transplantation (Basingstoke), 2008-06, Vol.41 (11), p.935-940

2008

Link zum Volltext

Verfügbarkeit prüfen

Coincident myelodysplastic syndrome and T‐cell large granular lymphocytic disease: clinical and pathophysiological features

British journal of haematology, 2001-01, Vol.112 (1), p.195-200

2001

Link zum Volltext

Verfügbarkeit prüfen

Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma

Bone marrow transplantation (Basingstoke), 2006-06, Vol.37 (12), p.1099-1102

2006

Link zum Volltext

Verfügbarkeit prüfen

Comparable kinetics of myeloablation between fludarabine full-dose busulfan and fludarabine melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation

Bone marrow transplantation (Basingstoke), 2006-10, Vol.38 (7), p.477-482

2006

Link zum Volltext

Verfügbarkeit prüfen

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment

JAMA : the journal of the American Medical Association, 2003-04, Vol.289 (13), p.1645

2003

Link zum Volltext

Verfügbarkeit prüfen

The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up

American journal of hematology, 2010-06, Vol.85 (6), p.403-408

2010

Link zum Volltext

Verfügbarkeit prüfen

Advances in experimental treatment of β-thalassaemia

Expert opinion on investigational drugs, 2001-05, Vol.10 (5), p.925-934

2001

Link zum Volltext

Verfügbarkeit prüfen

Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease

Blood, 2003-12, Vol.102 (12), p.3865-3870

2003

Link zum Volltext

Verfügbarkeit prüfen

HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome

Blood, 2002-09, Vol.100 (5), p.1570-1574

2002

Link zum Volltext

Verfügbarkeit prüfen

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes

Annals of internal medicine, 2002-08, Vol.137 (3), p.156

2002

Link zum Volltext

Verfügbarkeit prüfen

Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?

Seminars in hematology, 2000, Vol.37 (1), p.15-29

2000

Link zum Volltext

Verfügbarkeit prüfen

Normal and transforming functions of RUNX1: A perspective

Journal of cellular physiology, 2006-06, Vol.207 (3), p.582-593

2006

Link zum Volltext

Verfügbarkeit prüfen

DNA hypo‐methylating agents and sickle cell disease

British journal of haematology, 2004-09, Vol.126 (5), p.629-636

2004

Link zum Volltext

Verfügbarkeit prüfen

Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells

Cancer research (Chicago, Ill.), 1999-06, Vol.59 (12), p.2766-2769

1999

Link zum Volltext

Verfügbarkeit prüfen

Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome

Blood, 2001-12, Vol.98 (13), p.3513-3519

2001

Link zum Volltext

Verfügbarkeit prüfen

Clinical studies with fetal hemoglobin—enhancing agents in sickle cell disease

Seminars in hematology, 2004-10, Vol.41 (4), p.11-16

2004

Link zum Volltext

Verfügbarkeit prüfen

HLA‐DR4 predicts haematological response to cyclosporine in T‐large granular lymphocyte lymphoproliferative disorders

British journal of haematology, 2003-11, Vol.123 (3), p.449-453

2003

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 31

Suche als RSS-Feed

Aktive Filter

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(30)
Mit Volltextzugriff
(27)

Publikationsform

Artikel
(31)

Sprache

Englisch
(31)
Japanisch
(9)

Erscheinungsjahr

n.n

Thema

Science & Technology
(31)
Life Sciences & Biomedicine
(30)
Biological And Medical Sciences
(21)
Hematology
(21)
Medical Sciences
(21)
Adult
(15)
Hematologic And Hematopoietic Diseases
(15)
Middle Aged
(14)
Oncology
(14)
Female
(12)
Male
(12)
Aged
(9)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(8)
Genetic Aspects
(7)
Mutation
(7)
Animals
(6)
Gene Expression
(6)
Leukemia
(6)
Stem Cells
(6)

14 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms

CpG methylation patterns and decitabine treatment response in acute myeloid leukemia cells and normal hematopoietic precursors

Distinct iron architecture in SF3B1-mutant myelodysplastic syndrome patients is linked to an SLC25A37 splice variant with a retained intron

Novel homo- and hemizygous mutations in EZH2 in myeloid malignancies

A simple method to predict response to immunosuppressive therapy in patients with myelodysplastic syndrome

p53 Independent epigenetic-differentiation treatment in xenotransplant models of acute myeloid leukemia

CBL mutation-related patterns of phosphorylation and sensitivity to tyrosine kinase inhibitors

Dynamics of clonal evolution in myelodysplastic syndromes

Fludarabine i.v. BU conditioning regimen: myeloablative, reduced intensity or both?

Coincident myelodysplastic syndrome and T‐cell large granular lymphocytic disease: clinical and pathophysiological features

Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma

Comparable kinetics of myeloablation between fludarabine full-dose busulfan and fludarabine melphalan conditioning regimens in allogeneic peripheral blood stem cell transplantation

Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment

The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐up

Advances in experimental treatment of β-thalassaemia

Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease

HLA-DR15 (DR2) is overrepresented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome

Antithymocyte globulin for treatment of the bone marrow failure associated with myelodysplastic syndromes

Myelodysplastic syndrome and aplastic anemia: Distinct entities or diseases linked by a common pathophysiology?

Normal and transforming functions of RUNX1: A perspective

DNA hypo‐methylating agents and sickle cell disease

Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells

Increased frequency of HLA-DR2 in patients with paroxysmal nocturnal hemoglobinuria and the PNH/aplastic anemia syndrome

Clinical studies with fetal hemoglobin—enhancing agents in sickle cell disease

HLA‐DR4 predicts haematological response to cyclosporine in T‐large granular lymphocyte lymphoproliferative disorders

Aktive Filter

Suchergebnisse filtern